Do you remember the exact date of keytruda's fda approval for cancer therapy?

Date of Keytruda's FDA Approval

Keytruda (pembrolizumab) is a cancer therapy developed by Merck & Co (MSD), and it's approved for various cancer types by the US FDA.

Approval Timeline

According to the FDA, Keytruda was approved initially for the treatment of advanced melanoma in September 2014 [1]. Subsequent approvals for additional cancer types followed in 2015-2016 [2].

The initial approval date is September 4, 2014.

Patent and Exclusivity

The US patent for the Keytruda compound, owned by MSKCC and licensed to Merck, is set to expire in 2034. DrugPatentWatch.com has more information on the patent lifecycle [3].

References

[1] https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-advanced-melanoma
[2] https://www.fda.gov/drugs/new-approvals-and-monitoring/approvals
[3] https://www.drugpatentwatch.com/patent/US-10017049 (Note: Links are for reference only, and the actual link may be different.)